Scott Wasserman

Scott Wasserman

Director/Board Member at INHIBIKASE THERAPEUTICS, INC.

Net worth: - $ as of 31/10/2026

56 year
Health Technology
Consumer Services
Finance

Profile

Scott M.
Wasserman
is currently Chief Medical Officer at Kailera Therapeutics, Inc. since 2024 and Independent Director at Inhibikase Therapeutics, Inc. since 2026.
Formerly, Dr. Wasserman was Chief Executive Officer at Latigo Biotherapeutics, Inc. from 2019 to 2023, Venture Partner at Frazier Management LLC from 2023 to 2024, and Vice President & Global Development at Amgen, Inc. from 2015 to 2019.
Education includes an undergraduate degree from Haverford College conferred in 1992 and an undergraduate degree from Stanford University School of Medicine conferred in 2004.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
-.--%
16/04/2026 0 ( -.--% ) - $ 31/10/2026

Scott Wasserman active positions

CompaniesPositionStart
INHIBIKASE THERAPEUTICS, INC. Director/Board Member 19/10/2026

Former positions of Scott Wasserman

CompaniesPositionEnd
Private Equity Investor 01/10/2024
LATIGO BIOTHERAPEUTICS, INC. Chief Executive Officer 01/06/2023
AMGEN INC. Private Equity Investor 01/05/2019
See the detail of Scott Wasserman's experience

Education of Scott Wasserman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

89

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies7

Health Technology

Finance

Consumer Services

Consumer Services

Health Technology

Consumer Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Scott Wasserman